A Series D financing round has been successfully closed by Dewpoint Therapeutics a biotechnology company focused on transforming condensate biology into medicine. This funding will extend the company's operational runway into early 2027 and is intended to support the advancement of DPTX3186, a first-in-class condensate modulator (c-mod), into clinical trials by the end of 2025. The company aims to achieve early clinical proof-of-concept for this drug in gastric cancer by the end of 2026. The financing will also accelerate the development of another c-mod targeting MYC, which is considered a difficult-to-target protein, and will strengthen existing collaborations with pharmaceutical companies such as Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma.
DPTX3186 is an orally delivered small molecule c-mod with a new mechanism of action designed to selectively disrupt oncogenic Wnt signaling by forcing β-catenin to concentrate in an inactive condensate within cancer cells. This novel approach has the potential to overcome historical safety concerns, such as bone and gastrointestinal toxicity, that have limited previous Wnt-targeted therapies.
The Series D round received strong support from existing investors who are aligned with Dewpoint's strategic vision and scientific progress. According to Ameet Nathwani, MD, CEO of Dewpoint Therapeutics, this funding provides the opportunity to demonstrate the promise of condensate biology in the clinic and to establish a new class of condensate modulating therapeutics with broad potential. He expressed gratitude for the continued support and strategic guidance from investors and the board as the company enters its clinical development phase. Dewpoint's proprietary AI/ML-powered platform is the foundation of its drug discovery pipeline, which spans multiple therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. The company's work is based on the understanding that many diseases are regulated by or arise from the dysfunction of condensates, which are membraneless organelles that organize molecules within cells. Condensate-modulating drugs (c-mods) could therefore provide new therapeutic options for complex diseases and historically "undruggable" targets.